跳至主要内容
临床试验/IRCT20180428039456N1
IRCT20180428039456N1已完成3 期

The effect of Esmolol before cardioplegia and in the cardioplegic solution on the myocardial injury biomarkers in coronary artery bypass graft surgery patients

Esfahan University of Medical Sciences0 个研究点目标入组 280 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
已完成
入组人数
280

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
no limit 至 no limit(—)
性别
All

入选标准

  • Only coronary bypass grafting surgery candidates due to coronary artery disease and atherosclerosis
  • Left ventricular Ejection fraction between 45-60%
  • Left ventricle end diastole Diameter (LVEDD) less than 60 mm
  • Age above 18 years old
  • Not having diabetes mellitus type 2 or consuming any oral hypoglycemic agents
  • Not having severe systemic diseases (including any pulmonary, hepatic, renal, and musculoskeletal diseases or immune system illnesses)
  • Not participating in any other studies
  • Not having any confirmed arrhythmia or consuming any anti-arrhythmic agents (except beta-blockers)

排除标准

  • Not willing to participate in the study
  • No need for emergency operation
  • No history of inappropriate reaction to Esmolol
  • Not received Esmolol over the past 30 days

研究者

相似试验